Role of transporters in the distribution of platinum-based drugs

被引:76
|
作者
Harrach, Saliha [1 ]
Ciarimboli, Giuliano [1 ,2 ]
机构
[1] Univ Munster, Univ Hosp Munster, Med Clin D, Expt Nephrol, D-48149 Munster, Germany
[2] Univ Munster, Univ Hosp Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany
来源
关键词
cisplatin; oxaliplatin; transporters; side effects; uptake; ORGANIC CATION TRANSPORTERS; CISPLATIN-INDUCED NEPHROTOXICITY; ADENOSINE-TRIPHOSPHATASE ATP7B; CELLULAR PHARMACOLOGY; COPPER TRANSPORTERS; OXALIPLATIN; RESISTANCE; CARBOPLATIN; TOXICITY; CTR1;
D O I
10.3389/fphar.2015.00085
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum derivatives used as chemotherapeutic drugs such as cisplatin and oxaliplatin have a potent antitumor activity. However, severe side effects such as nephro-, oto-, and neurotoxicity are associated with their use. Effects and side effects of platinum-based drugs are in part caused by their transporter-mediated uptake in target and non target cells. In this mini review, the transport systems involved in cellular handling of platinum derivatives are illustrated, focusing on transporters for cisplatin. The copper transporter 1 seems to be of particular importance for cisplatin uptake in tumor cells, while the organic cation transporter (OCT) 2, due to its specific organ distribution, may play a major role in the development of undesired cisplatin side effects. In polarized cells, e.g., in renal proximal tubule cells, apically expressed transporters, such as multidrug and toxin extrusion protein 1, mediate secretion of cisplatin and in this way contribute to the control of its toxic effects. Specific inhibition of cisplatin uptake transporters such as the OCTs may be an attractive therapeutic option to reduce its toxicity, without impairing its antitumor efficacy.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials
    Arantseva, D. A.
    Vodovozova, E. L.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2018, 44 (06) : 619 - 630
  • [32] The side effects of platinum-based chemotherapy drugs: a review for chemists
    Oun, Rabbab
    Moussa, Yvonne E.
    Wheate, Nial J.
    DALTON TRANSACTIONS, 2018, 47 (19) : 6645 - 6653
  • [33] The interaction of platinum-based drugs with native biologically relevant proteins
    Brauckmann, Christine
    Wehe, Christoph A.
    Kieshauer, Michael
    Lanvers-Kaminsky, Claudia
    Sperling, Michael
    Karst, Uwe
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (06) : 1855 - 1864
  • [34] The interaction of platinum-based drugs with native biologically relevant proteins
    Christine Brauckmann
    Christoph A. Wehe
    Michael Kieshauer
    Claudia Lanvers-Kaminsky
    Michael Sperling
    Uwe Karst
    Analytical and Bioanalytical Chemistry, 2013, 405 : 1855 - 1864
  • [35] Roles of nuclear proteins in the anticancer activity of platinum-based drugs
    Xu, Dong
    Barnes, Katie R.
    Danford, Andrew J.
    Wang, Dong
    Wang, Qun
    Tullius, Thomas D.
    Lippard, Stephen J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2130 - U2130
  • [36] Synergy between PPARγ ligands and platinum-based drugs in cancer
    Girnun, Geoffrey D.
    Naseri, Elnaz
    Vafai, Scott B.
    Qu, Lishu
    Szwaya, Jeffrey D.
    Bronson, Roderick
    Alberta, John A.
    Spiegelman, Bruce M.
    CANCER CELL, 2007, 11 (05) : 395 - 406
  • [37] Role of ABC transporters in the pharmacokinetics and tissue distribution of drugs
    Sugiyama, Y.
    FEBS JOURNAL, 2007, 274 : 45 - 45
  • [38] Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs
    Qin, Zhiying
    Ren, Guanghui
    Yuan, Jinjie
    Chen, Huili
    Lu, Yang
    Li, Ning
    Zhang, Yongjie
    Chen, Xijing
    Zhao, Di
    FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [39] Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs
    Famurewa, Ademola C.
    Mukherjee, Anirban Goutam
    Wanjari, Uddesh Ramesh
    Sukumar, Aarthi
    Murali, Reshma
    Renu, Kaviyarasi
    Vellingiri, Balachandar
    Dey, Abhijit
    Gopalakrishnan, Abilash Valsala
    LIFE SCIENCES, 2022, 305
  • [40] Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
    Shahlaei, Mona
    Asl, Shaahin Mohammadzadeh
    Derakhshani, Atefe
    Kurek, Leonie
    Karges, Johannes
    Macgregor, Robert
    Saeidifar, Maryam
    Kostova, Irena
    Saboury, Ali Akbar
    JOURNAL OF MOLECULAR STRUCTURE, 2024, 1301